OPKO Health
OPKO Health, Inc. operates as a healthcare company, in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. Based in Miami.
OPKO Health: sales sharply down (−55.0%), net income sharply up (+39.9%), cash flow sharply up (+35.1%).
- Sales sharply downFirst nine months 2026
Revenue: $206M, vs. $458M a year earlier, i.e. −55.0%.
- Net income sharply upFirst nine months 2026
Net income: $−117M, vs. $−194M a year earlier, i.e. +39.9%.
- Cash flow sharply upFirst nine months 2026
Operating cash flow: $−99M, vs. $−153M a year earlier, i.e. +35.1%.
- Operating income downFirst nine months 2026
Operating income: $−81M, vs. $−79M a year earlier, i.e. −3.0%.
What the market pays, vs. the sector
This company's valuation multiples history is being built day by day from now on.
P/E calculated on net income (trailing 12 months: last fiscal year + 2026 year-to-date − same period a year earlier). Sector median: companies in the — group tracked here. Prices: Yahoo Finance; market cap cross-checked with the Tel Aviv Stock Exchange for Israeli stocks. These ratios describe a price, not a value: none of them says whether the share is expensive or cheap.
Follow earnings · WhatsApp group TA-125Details ▾
Every report from a TA-125 company, analyzed the same day: key figures and year-on-year change, analysis in brief, share price reaction. One daily summary during earnings season.
Join the TA-125 groupDetailed figures and history
Financial summary
| 9 months 2026 | 9 months 2025 | FY 2025 | |
|---|---|---|---|
| Total assets | 1,880 | 1,996 | 1,932 |
| Current assets | 806 | 627 | 582 |
| Non-current assets | 1,074 | 1,368 | 1,350 |
| Equity | 1,116 | 1,305 | 1,268 |
| of which minority interests | 0 | 0 | 0 |
| Current liabilities | 162 | 169 | 147 |
| Non-current liabilities | 602 | 521 | 517 |
| Revenue | 206 | 458 | 607 |
| Gross profit | 136 | 142 | 206 |
| Operating income | −81 | −79 | −117 |
| Pre-tax income | −105 | −194 | −241 |
| Net income | −117 | −194 | −226 |
| Net income (attributable to shareholders) | −117 | −194 | −226 |
| Dividends paid | 0 | 0 | 0 |
| Operating cash flow | −99 | −153 | −179 |
In millions of dollars. The "H1" columns cover the first six months of the year.
Calculated from these figures
| 9 months 2026 | 9 months 2025 | FY 2025 | |
|---|---|---|---|
| Gross margin | 65.7% | 31.0% | 33.9% |
| Operating margin | −39.4% | −17.3% | −19.3% |
| Net margin | −56.6% | −42.4% | −37.2% |
| Current ratio (current assets / current liabilities) | 5,0 x | 3,7 x | 4,0 x |
| Equity / total assets | 59.4% | 65.4% | 65.6% |
The 5-year history, charts and cross-check models are coming for companies listed only in Tel Aviv: each new filing on Maya is kept and enriches the page.
Company overview
OPKO Health, Inc. operates as a healthcare company, in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company operates in two segments, Pharmaceutical and Diagnostics. The Pharmaceutical segment develops MDX2001, a tetra-specific antibody targeting several types of solid tumors in Phase 1 clinical trials; MDX2003, a tetra-specific antibody targeting two antigens for hematological tumors in Phase 1 clinical trials; and MDX2004, a trispecific immune modulator to rebuild and sustain the patient's own immune system. This segment also engages in the development of Epstein Barr Virus vaccine; Rayaldee, a patented extended-release product for oral administration containing 30 mcg of a prohormone; OPK-88006 oral and injectable product to regulate blood glucose and reduce body weight; NGENLA, recombinant human growth hormone product developed for the long-term treatment of pediatric patients with growth hormone deficiency. The Diagnostics segment offers laboratory testing services, such as detection, diagnosis, evaluation, monitoring, and treatment of diseases, as well as esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare under the BioReference brand; and 4Kscore test.
Source: official company profile (Yahoo Finance), summary. Website: www.opko.com
- Maya, Tel Aviv Stock Exchange: company page and reports
No dividend paid over the past five years (source: Yahoo Finance).